Loading...
•
Jun 30, 2021
Aldeyra Q2 2021 Earnings Report
Reported financial results for the second quarter of 2021 and recent corporate highlights.
Key Takeaways
Aldeyra Therapeutics reported a net loss of $14.9 million for the quarter ended June 30, 2021, compared to a net loss of $7.5 million for the same period in 2020. As of June 30, 2021, cash and cash equivalents totaled $249.7 million.
Top-line results from Phase 3 TRANQUILITY and TRANQUILITY-2 clinical trials of Reproxalap in dry eye disease are expected in the fourth quarter of 2021.
The U.S. FDA granted Orphan Drug Designation to ADX-2191 for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa.
Initial results from Phase 2 clinical trials of oral RASP inhibitor ADX-629 in multiple systemic indications are anticipated in the fourth quarter of 2021 or first quarter of 2022.
Cash and cash equivalents were $249.7 million as of June 30, 2021, projecting a cash runway through 2023.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...